1. Benseler, F. ; Fu , D.J. ; Ludwig, J.; McLaughlin , L.W.
Hammerhead-like Molecules Containing Non -Nucleoside Linkers Are Active RNA catalysts.
J.Am.Chem.Soc . 1993, 115, 8483-8484

2. Dunkel M, Reither V, Ebelwill S, Ludwig J.
Synthesis of 2'-C-Difluoromethyl substituted Nucleoside Analogs as Ribonucleoside Replacements in Hammerhead Ribozymes.
Nucleosides & Nucleotides. 1995;14:799-801.

3. Desjardins JP, Sproat BS, Beijer B, Blaschke M, Dunkel M, Gerdes W, Ludwig J, Reither V, Rupp T, Iversen PL.
Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
Journal of Pharmacology and Experimental Therapeutics. 1996;278(3):1419-1427.

4. Lyngstadaas, S.P.; Sproat, B. S.; Blaschke, M.; Ludwig, J.; Rupp, T.; Prydz, H.P.
In vivo Knockout of a Tissue-Specific Gene by Synthetic Ribozymes
Methods in Molecular Medicine 1998, 11 , 371-387.

5. Ludwig J, Blaschke M, Sproat BS.
Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine(15.1) to inosine(15.1) changes the cleavage site specificity from (NUH17)-U-16.2-H-16.1 to (NCH17)-C-16.2-H-16.1.
Nucleic Acids Research. 1998;26(10):2279-2285.

6 Ludwig J, Blaschke M, Dunkel M, Beijer B, Ross K, Sproat BS.
Structural requirements at the 15.1-16.1 position of the hammerhead ribozyme.
Nucleosides and Nucleotides. 1999;18:1519-1520.

7. Caselmann WH, Serwe M, Lehmann T, Ludwig J, Sproat BS, Engels JW.
Design, delivery and efficacy testing to therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo.
World Journal of Gastroenterology. 2000;6(5):626-629.

8. Salmi, P.; Sproat, B.S.; Ludwig, J.; Hale, R.; Avery, N.; Kela, J.; Wahlestedt, C.
Dopamine D2 receptor ribozyme inhibits quinpirole induced stereotypy in rats
Eur. Journal of Pharmacology 2000, 388 R1-R2

9. Gonzalez-Carmona MA, Schussler S, Serwe M, Alt M, Ludwig J, Sproat BS, Steigerwald R, Hoffmann P, Quasdorff M, Schildgen O, Caselmann WH.
Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells.
Journal of Hepatology. 2006;44(6):1017-1025.